Intestine Transplant in India and UAE | Complete Patient Guide

• ELIGIBLE DIAGNOSES (INDICATIONS):

• Irreversible intestinal failure with dependence on total parenteral nutrition (TPN) for >12 months

• Short bowel syndrome with residual small bowel <100 cm (adult) or <20–25 cm (neonate/infant) without intact colon

• Crohn's disease with extensive small bowel resection and TPN-associated complications

• Mesenteric vascular occlusion (superior mesenteric artery thrombosis or embolism) with massive gut infarction

• Radiation enteritis with pan-intestinal dysfunction

• Chronic intestinal pseudo-obstruction (CIPO) refractory to prokinetics and surgical interventions

• Microvillus inclusion disease (MVID) and tufting enteropathy in paediatric patients

• Abdominal desmoid tumour involving the mesenteric root precluding conventional resection

• Familial adenomatous polyposis (FAP) with extensive mesenteric desmoid disease

• Functional short gut in patients who have lost all central venous access sites (catheter salvage failure)

• Recurrent life-threatening catheter-related bloodstream infections (≥2 per year with systemic sepsis)

• TPN-associated liver disease (TPNALD) progressing to fibrosis/cirrhosis → indication for combined liver-intestine or multi-visceral transplant

• GRAFT TYPE SELECTION CRITERIA:

• Isolated intestinal transplant: intestinal failure WITHOUT significant liver disease (bilirubin <3 mg/dL, no portal hypertension, no fibrosis on biopsy)

• Combined liver-intestine transplant: intestinal failure WITH established TPNALD (biopsy-proven fibrosis/cirrhosis, bilirubin >3–5 mg/dL, portal hypertension)

• Full multi-visceral transplant (stomach + duodenum + pancreas + intestine ± liver): gastric dysmotility, extensive mesenteric thrombosis involving portomesenteric venous system, or portal vein thrombosis precluding standard vascular reconstruction; also Gardner syndrome/desmoid tumours requiring en-bloc resection

• Modified multi-visceral (without liver): portal hypertension with preserved hepatic function but complex mesenteric vascular anatomy

• REQUIRED PRE-TRANSPLANT DIAGNOSTIC WORKUP:

• Contrast-enhanced CT angiography of abdomen/pelvis (mesenteric vascular anatomy, portal vein patency, residual bowel mapping)

• MRI enterography (mucosal disease assessment, fistula mapping in Crohn's)

• Liver biopsy (staging of TPNALD — Ishak or METAVIR scoring)

• Transthoracic echocardiography (ECHO) with Doppler (cardiac function, pulmonary hypertension screen — PA systolic pressure >35 mmHg is a relative contraindication)

• Pulmonary function tests (FEV1, DLCO — respiratory reserve assessment)

• Bone density scan (DEXA) — TPN patients frequently have severe osteopaenia

• Serological panel: CMV IgG, EBV IgG, HSV, VZV, HIV, HBsAg, HBcAb, HCV RNA, HTLV-I/II, RPR/TPHA (syphilis), Toxoplasma IgG

• HLA typing (Class I and II) and Panel Reactive Antibody (PRA) / donor-specific antibody (DSA) screening — critical for crossmatch strategy

• Blood group and extended red cell antigen typing

• Full metabolic panel: liver function, kidney function (eGFR — tacrolimus nephrotoxicity risk stratification), coagulation (PT, INR, factor V level)

• Nutritional biochemistry: 25-OH Vitamin D, zinc, selenium, magnesium, phosphorus, thiamine, folate, B12

• Psychiatric evaluation and social work assessment (medication adherence potential, caregiver support structure — mandatory component)

• Age-appropriate cancer screening: colonoscopy, mammography, PAP smear, PSA, low-dose CT chest

• ABSOLUTE CONTRAINDICATIONS:

• Uncontrolled systemic sepsis or multi-drug-resistant organism (MDRO) colonisation that cannot be cleared

• Active or recent (within 5 years) extra-hepatic malignancy without documented complete remission

• Severe irreversible cardiopulmonary dysfunction (LVEF <30%, mean PAP >35 mmHg on right heart catheterisation)

• Uncontrolled autoimmune disease with high-dose immunosuppression requirements that would be compounded

• Active alcohol or substance dependence without documented rehabilitation

• Demonstrated and persistent non-compliance with prior medical regimens (psychiatric evaluation mandatory)

• Significant neurological impairment precluding understanding of post-transplant care demands

• RELATIVE CONTRAINDICATIONS (case-by-case multidisciplinary review):

• Morbid obesity (BMI >35 kg/m² — operative and wound healing risk)

• Advanced chronic kidney disease (eGFR <30 mL/min — calcineurin inhibitor nephrotoxicity will accelerate progression)

• Prior extensive abdominal surgeries with hostile abdomen (mesh, dense adhesions — surgical feasibility assessment required)

• High PRA (>50%) or pre-formed donor-specific antibodies (require desensitisation protocols)

• CMV D+/R− mismatch (manageable with extended prophylaxis but increases risk of severe CMV disease)

GRAFT TYPES AND SURGICAL TECHNIQUES:

1. ISOLATED INTESTINAL TRANSPLANT (IIT):

The allograft consists of the donor jejunum and ileum, typically 150–200 cm, preserving the ileocaecal valve where possible to enhance absorption and reduce bacterial translocation. Vascular reconstruction is achieved by end-to-side anastomosis of the donor superior mesenteric artery (SMA) to the recipient infrarenal aorta, and the donor portal/superior mesenteric vein (SMV) to the recipient SMV or infrarenal inferior vena cava (IVC). The proximal bowel is anastomosed in a Roux-en-Y or straight end-to-end/side-to-side configuration depending on recipient anatomy. A distal loop ileostomy (Bishop-Koop or standard end ileostomy) is created to allow direct endoscopic surveillance of the allograft mucosa — this is a defining feature of intestinal transplant management. Stoma reversal is typically planned at 6–12 months post-transplant in stable patients.

2. COMBINED LIVER-INTESTINE TRANSPLANT:

The liver and small bowel are transplanted as a composite allograft sharing the hepatic vessels and portal venous system. The donor coeliac axis and SMA are often retained on a Carrel patch. This is technically preferred over sequential transplantation when TPNALD has caused portal hypertension, as the shared venous drainage eliminates the need for complex venous reconstruction. The liver graft confers partial immunological protection to the intestinal allograft (the 'immunological umbrella' effect), permitting marginally lower tacrolimus targets and potentially reducing rejection burden.

3. FULL MULTI-VISCERAL TRANSPLANT (MVTx):

En-bloc procurement and implantation of the stomach, duodenum, head of pancreas, small bowel, and liver (and occasionally colon). This is the most physiologically complete reconstruction and is required when the native upper gastrointestinal tract is non-functional (as in diffuse mesenteric thrombosis or pan-alimentary dysmotility). Arterial inflow is via a bifurcated donor aortic conduit encompassing both the coeliac and superior mesenteric axes. Venous outflow is through the donor IVC (piggyback or classical technique). Total operative time typically ranges 10–18 hours with a multidisciplinary team including transplant surgeons, hepatobiliary surgeons, vascular surgeons, and anaesthesiologists expert in massive transfusion protocols.

4. MODIFIED MULTI-VISCERAL TRANSPLANT (without liver):

For patients requiring stomach and pancreatoduodenal replacement but with preserved hepatic function and non-cirrhotic portal hypertension. Preserves the native liver, reducing cholestatic complications and bile duct reconstruction complexity.

5. DONOR SELECTION AND ORGAN PROCUREMENT:

• Deceased donor (cadaveric, brain-dead or, increasingly, donation after circulatory death — DCD) is the standard source.

• Living donor intestinal transplant (LDIT): highly specialised, involving 150–200 cm segmental small bowel donation from an ABO-compatible related donor. Only a handful of centres worldwide perform this routinely. Not yet widely available in India or the UAE but under development at select academic centres.

• Cold ischaemia time is critically limited to <8–10 hours for intestinal grafts (compared with 24 hours for kidneys), placing extreme logistical demands on procurement and implantation teams.

• Machine perfusion (normothermic or hypothermic): emerging technology for intestinal graft preservation. Normothermic machine perfusion (NMP) with oxygenated perfusate allows ex-vivo viability assessment (bile production for liver component, peristaltic activity, mucosal integrity fluorescence) before implantation. Available at select centres in India's metro transplant hubs.

6. IMMUNOSUPPRESSION PROTOCOLS (DRUG CLASSES AND TARGETS):

• Induction: rATG (rabbit anti-thymocyte globulin, 1.5 mg/kg/day for 3–5 days) OR basiliximab (IL-2R antagonist, 20 mg on days 0 and 4) — centre-dependent

• Maintenance backbone: Tacrolimus (calcineurin inhibitor) — trough targeting 12–15 ng/mL months 1–3, reducing to 8–12 ng/mL thereafter

• Adjunct maintenance: Mycophenolate mofetil (MMF) 500–1000 mg twice daily; role is more limited than in kidney transplant due to mucosal side effects

• mTOR inhibitors (sirolimus, everolimus): used selectively in EBV+ / PTLD-risk patients or as calcineurin-sparing agents for nephrotoxicity

• Corticosteroids: pulsed methylprednisolone (500–1000 mg IV) for ACR treatment; rapid taper targeting steroid-free maintenance by 6–12 months in stable patients

• Novel and investigational agents: Belatacept (CTLA4-Ig co-stimulation blockade), Vedolizumab (gut-selective anti-integrin — investigational for chronic rejection), donor-specific regulatory T-cell therapy (Treg infusions — in clinical trials at ITR centres)

7. REJECTION SURVEILLANCE TECHNOLOGY:

• Wireless capsule endoscopy: used in centres with stoma reversal to monitor distal allograft mucosa non-invasively

• Citrulline plasma levels: functional biomarker of enterocyte mass; levels <20 µmol/L correlate with significant rejection or villous atrophy

• Donor-derived cell-free DNA (dd-cfDNA): emerging liquid biopsy marker for early rejection detection, now validated in intestinal transplant (analogous to AlloSure in kidney transplant)

• Confocal laser endomicroscopy: allows real-time in-vivo histology at the time of surveillance endoscopy

8. NUTRITIONAL REHABILITATION STRATEGY:

• Phase 1 (immediate post-transplant): TPN continued; enteral feeding initiated via nasojejunal or jejunostomy tube within 24–72 hours at trophic rates (10–20 mL/hour elemental formula)

• Phase 2 (weeks 2–6): Gradual advancement of enteral feeds correlated with ileostomy output (<1200 mL/day target); TPN weaned in parallel

• Phase 3 (months 1–6): Introduction of oral diet (low-oxalate, low-fat, high-complex carbohydrate); loperamide and oral rehydration solutions to control output

• Phase 4 (months 6–12): TPN independence — the primary functional outcome; achieved in approximately 75–80% of survivors at one year

• Gut rehabilitation pharmacotherapy: Teduglutide (GLP-2 analogue) may be used in the pre-transplant period to maximise residual bowel adaptation and potentially avoid or delay transplantation

PHASE 1 — INTERNATIONAL PATIENT EVALUATION (Weeks 1–4 before transplant listing):

• GAF Healthcare coordinates submission of complete medical records (operative reports, TPN prescription, liver biopsy, imaging, serology) to the selected transplant centre for remote triage review by the transplant hepatologist and surgeon

• Virtual MDT (multidisciplinary team) consultation conducted via video conferencing — patient and family receive a preliminary transplant suitability assessment and graft type recommendation

• Travel to India or UAE for in-person evaluation: 3–5 days of outpatient investigations including CT angiography, ECHO, PFTs, crossmatch serology, HLA typing, and psychiatric/social work assessment

• Formal MDT listing decision communicated within 5–7 business days of completed workup

• Patient registered on the national waiting list (NOTTO — National Organ and Tissue Transplant Organisation — in India; Dubai Health Authority organ procurement registry in UAE)

• Waiting period: variable (weeks to months depending on donor availability, blood group, and body size matching); paediatric patients often have shorter waits due to paediatric donor priority schemes

PHASE 2 — PRE-TRANSPLANT OPTIMISATION (Waiting period):

• Patient and one adult family caregiver required to reside within 2–4 hours of the transplant centre (GAF Healthcare arranges serviced medical accommodation)

• Continuation of TPN via existing central venous access; regular outpatient monitoring (weekly LFTs, tacrolimus levels if pre-sensitised, nutritional biochemistry)

• Infection clearance: any active CRBSI treated and line changed before activation on waiting list

• Optimisation of bone density (IV bisphosphonate if severe osteopaenia), cardiac function, and nutritional status

• Patient and caregiver education sessions: stoma care, medication administration, rejection symptom recognition, food safety protocols

• 24/7 on-call availability required — transplant call can occur at any hour with typically 4–6 hours notice from organ offer to operative start

PHASE 3 — TRANSPLANT SURGERY DAY:

• Organ offer received; crossmatch performed urgently (flow cytometry crossmatch, typically 2–4 hours)

• Patient admitted and undergoes final pre-operative assessment: blood count, coagulation, electrolytes, ECG, anaesthesia review

• Induction immunosuppression administered (rATG Day 0)

• Operative duration: 6–10 hours (isolated intestinal transplant); 10–18 hours (multi-visceral transplant)

• Intraoperative monitoring: arterial line, central venous catheter, pulmonary artery catheter or transoesophageal echocardiography (TOE) for haemodynamic guidance; cell salvage (autotransfusion) used where oncologically safe

• Immediate post-operative transfer to transplant-dedicated ICU or multi-organ transplant unit

PHASE 4 — ICU AND EARLY POST-OPERATIVE PERIOD (Days 1–21):

• Days 1–3: Mechanical ventilation, haemodynamic stabilisation, fluid balance optimisation, vasopressor weaning; tacrolimus initiated enterally or IV once haemodynamically stable

• Days 3–5: Extubation if respiratory parameters adequate; first surveillance endoscopy via ileostomy (visual assessment of mucosal perfusion, colour, peristalsis)

• Days 5–7: Trophic enteral feeds initiated via jejunostomy; TPN continued in parallel; first protocol biopsy

• Days 7–14: Surveillance endoscopy + biopsy twice weekly; tacrolimus trough monitoring daily; CMV PCR and EBV PCR twice weekly; gradual advancement of enteral feeds if biopsy clear

• Day 14–21: Transition from ICU to transplant step-down ward if: haemodynamically stable, no acute rejection on biopsy, tolerating enteral feeds at 30–50% of caloric target, wound healing satisfactory

PHASE 5 — WARD REHABILITATION (Days 21–60):

• Weekly then biweekly surveillance endoscopy with biopsy; pathology reviewed by transplant pathologist using Ruiz grading scale (Grade 0 — no rejection; Grade 1 — mild indeterminate; Grade 2 — mild ACR; Grade 3 — moderate ACR; Grade 4 — severe ACR)

• Gradual advance of oral diet under transplant dietitian supervision; tracking ileostomy output daily

• Physical and occupational therapy initiated: progressive mobilisation, reconditioning from prolonged pre-transplant debility

• Medication reconciliation and patient education: patient must self-administer tacrolimus, mycophenolate, prophylactic antimicrobials, and monitor own vital signs by discharge

• Target TPN independence (partial or full) before discharge

PHASE 6 — PRE-DISCHARGE AND FIT-TO-FLY ASSESSMENT (Weeks 12–20):

• International patients cleared for repatriation only when ALL of the following criteria are met:

a) Minimum 90 days post-transplant

b) No acute rejection episode in preceding 4 weeks (biopsy-confirmed)

c) Stable tacrolimus troughs within therapeutic range for ≥4 consecutive weeks

d) CMV and EBV PCR undetectable for ≥4 weeks

e) Tolerating ≥75% of caloric requirements enterally or orally (significant TPN reduction or full independence)

f) Patient and caregiver independently competent in all self-care tasks

g) Receiving transplant programme in home country identified and care plan transmitted

• GAF Healthcare coordinates medical escort (transplant nurse or physician) for long-haul repatriation flights where clinically indicated

• Comprehensive discharge package: full medication list, drug levels, biopsy reports, immunisation record, 24-hour emergency contact for home-country physician

PHASE 7 — LONG-TERM FOLLOW-UP (Months 6–60+):

• Monthly remote follow-up via GAF Healthcare telemedicine platform for first year (tacrolimus levels, renal function, nutritional biochemistry, rejection biomarkers)

• Annual in-person review at transplant centre recommended at 1 year and 3 years

• Life-long immunosuppression mandatory; never self-discontinue

• Stoma reversal surgery: planned at 6–12 months in stable patients

• Vaccination update: all live vaccines permanently contraindicated; inactivated annual influenza, PneumoVax, and COVID-19 booster recommended